Spaceflight Scrambles the Gut Microbiome and May Raise Cancer Risk in Astronauts

Going to space does something unsettling to the trillions of microbes living in the human gut, and a sweeping new review suggests the fallout could extend all the way to cancer biology. Prakrathi Keremane, Amèlia Jansen van Vuuren, Kamalesh Dattaram Mumbrekar, and Charlot Vandevoorde, writing in Life Sciences in Space Research, synthesize data from astronaut cohorts and ground-based animal studies to argue that the gut microbiome is not merely disrupted by spaceflight but pushed toward a state that may actively prime the body for tumor development. With Mars missions on the horizon, the stakes of that argument are hard to overstate.

Microgravity and Radiation Together Drive Gut Dysbiosis

The review identifies two overlapping stressors as the primary culprits: microgravity and space radiation. Neither operates in isolation. Microgravity alters fluid dynamics and mechanical cues in the intestine, changing the physical environment that gut bacteria inhabit. Radiation, especially the galactic cosmic rays that saturate deep space beyond Earth's protective magnetosphere, damages intestinal tissue directly and also selectively kills or disadvantages certain microbial populations. Together, the authors write, these forces drive gut dysbiosis, a loss of the normal balance and functional diversity of the microbial community.

Data from spaceflight microbial disruption studies have consistently documented shifts in community composition during and after missions, including a rise in the Firmicutes-to-Bacteroidetes ratio that marks wider spaceflight-associated microbiome changes. What the new review does is trace the downstream molecular consequences of those shifts with unusual specificity, connecting microbial imbalance to compromised epithelial integrity, elevated pro-inflammatory cytokines, and impaired immune surveillance. In other words, the gut wall becomes leakier, the immune system less capable of catching rogue cells, and the chemical environment more hospitable to the kind of chronic inflammation that underpins many cancers.

Oncogenic Signaling: What Dysbiosis Actually Does to Astronaut Biology

The mechanistic thread at the center of the review is the pathway from microbial imbalance to pro-oncogenic signaling. When protective commensals are displaced and potentially pathogenic species expand, they produce metabolites and trigger immune responses that can activate tumor-promoting pathways. The review draws on animal research showing that deep space galactic cosmic radiation can severely damage gastrointestinal tissue, raising the probability of tumor development in the stomach and colon. That finding, from a study published in PNAS, provides independent experimental grounding for the biological chain the authors describe: radiation injures tissue, dysbiosis follows, and the resulting inflammatory milieu amplifies oncogenic signaling.

The practical implication is that long-duration missions, think months-long transits to Mars rather than stays on the International Space Station, expose astronauts to cumulative radiation doses and sustained microgravity for long enough that these changes may become clinically meaningful. Short ISS missions of a few months may allow the microbiome to recover after return to Earth. A three-year round trip to Mars would not offer that reprieve.

How Researchers Have Studied This: Animal Models and Astronaut Cohorts

The review synthesizes two categories of evidence. Astronaut cohort data provide real-world observations but are limited by small sample sizes and the practical difficulties of collecting microbiome samples during missions. Ground-based animal models fill in the mechanistic gaps.

One well-established approach uses hindlimb unloading in rodents to simulate microgravity, combined with 16S rRNA sequencing and untargeted metabolomics to characterize shifts in both microbial community structure and the metabolites those communities produce. Research using simulated microgravity in mouse models with metabolomics readouts has documented long-term changes in gut microbiota composition and the metabolome, providing mechanistic detail that astronaut studies alone cannot supply. The combination of 'omics approaches, cataloguing both the microbes present and the chemicals they make, is increasingly the standard for linking microbial shifts to downstream biological effects.

In-flight animal experiments aboard spacecraft have added another layer, confirming that the microgravity signal is real and not merely an artifact of the stress of confinement or altered diet that ground models cannot fully replicate.

Open Questions About Causality and Individual Variation

The review is careful to note what remains unresolved. A fundamental limitation running through the entire field is that it is not yet fully clear whether observed microbiome changes directly cause the immune dysfunction and epithelial damage seen in spaceflight, or whether both are parallel consequences of the same upstream stressors. As researchers have noted, the link between spaceflight gut microbiota changes and clinical health outcomes in astronauts remains difficult to establish definitively, partly because the population of people who have actually flown in space is small and the follow-up periods for cancer incidence are long.

Individual variation adds another layer of uncertainty. Astronauts arrive at the launch pad with different baseline microbiomes, different dietary histories, and different genetic predispositions. How those factors interact with spaceflight stressors to determine individual risk is not yet mapped. The authors also acknowledge that most animal studies use relatively short exposure windows and radiation doses that may not perfectly replicate the specific spectral quality of deep-space galactic cosmic radiation.

Microbiome-Targeted Countermeasures for Future Deep-Space Missions

The final section of the review turns from diagnosis to potential intervention. The authors examine microbiome-targeted countermeasures, broadly comprising dietary strategies, prebiotics, and probiotics, as tools for preserving gut homeostasis during missions. Probiotics have shown promise as countermeasures to spaceflight health risks, but as that work notes, intervention studies conducted during actual missions are still needed to validate their effectiveness under real spaceflight conditions.

Beyond supplementation, the review flags comprehensive gut microbiome monitoring, combining microbial community profiling with metabolite tracking, as a strategy for detecting dysbiosis early and evaluating whether interventions are working. That kind of real-time biosurveillance may be technically feasible with compact sequencing hardware and would allow mission physicians to adjust countermeasures before damage accumulates.

The authors frame managing gut health not as a secondary wellness concern but as a core component of radiation risk mitigation for long-duration human spaceflight. If the oncogenic pathway they describe holds up under further scrutiny, then a probiotic or a dietary fiber protocol could one day sit alongside shielding and mission duration limits as a tool for keeping Mars-bound crews cancer-free on the journey there.